Veterinary Dermatology Drugs Market Size, Share & Trends Analysis Report By Indication, By Type, By Animal Type, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Veterinary Dermatology Drugs Market Trends

The global veterinary dermatology drugs market size was estimated at USD 17.36 billion in 2024 and is estimated to grow at a CAGR of 9.60% from 2025 to 2030. Increasing pet ownership, a growing number of dermatology drugs clinical trials and approval, a rising incidence rate of parasitic and other skin diseases in animals, and investments by market players are the key market growth drivers. For instance, in September 2024, The FDA approved Zenrelia (ilunocitinib tablets), an oral immunosuppressant for managing itching and atopic dermatitis in dogs over one year old. Elanco sponsored it. Zenrelia is available by prescription and has multiple tablet strengths.

Skin diseases are common in animals, affecting both domestic pets and livestock. Various factors can contribute to these conditions, including parasites, allergies, infections, environmental factors, and genetic predisposition. Some common skin diseases in animals include flea allergy dermatitis, atopic dermatitis, ringworm, bacterial and fungal infections, and others. According to the article published in the World Veterinary Journal in September 2024, Skin disorders are a significant issue in veterinary medicine globally, with studies showing prevalence rates of 21.4% in the UK, 17% in Iran, and 12%-27.6% in India among dogs. These conditions are a common concern in small animal practices. In addition, environmental changes, such as climate variations, pollution, and allergens, have increased skin-related problems in pets, further driving the demand for veterinary dermatology drugs.

Indication Insights

The parasitic infections segment dominated the market and held the largest revenue share of 42.49% in 2024. According to a February 2023 study published in Parasites & Vectors, the prevalence of tick infestation across European countries of Germany and Austria was estimated to be about 79% in dogs and 69% in cats. This high prevalence is expected to drive the demand for medications to prevent and manage these parasites.

The allergic infections segment is expected to witness the fastest CAGR of over 9.9% during the forecast period. The rising incidence of ailments such as atopic dermatitis and other itch disorders, particularly in companion animals, is anticipated to support market growth. In addition, more pet owners are making pet care decisions, which is projected to drive market growth. Furthermore, allergic dermatitis is the most prevalent form of skin condition in dogs; according to 2023 Frontiers Media S.A., twenty to thirty percent of dogs have an allergic dermatitis of some kind. One of the most significant symptoms of allergic dermatitis is pruritus, which is also frequently the most difficult to take care of.

Type Insights

The prescription segment dominated the veterinary dermatology drugs industry in 2024. Most dermatologist-prescribed skin drugs are taken orally, generally in the form of a delicious, chewable tablet. Veterinarians believe that some regions are experiencing increased resistance to fleas and ticks to ingredients in over-the-counter preventatives. Different compounds that may be more effective are utilized in prescription skin disease treatments. They are only available with the guidance of a veterinarian since they have a reduced margin of error when it comes to safe, effective use.

The OTC segment is anticipated to grow at the fastest CAGR of about 9.7% from 2025 to 2030. Customers can purchase over-the-counter (OTC) dermatology products online, in shops, and in pharmacies. Over-the-counter medications are applied topically to a pet's skin to treat fleas and ticks, either as spot-on drops or as a collar that delivers the medication over time. A prescription is not necessary for the majority of topical flea and tick medications, including spot-on treatments, a Seresto collar, and flea and tick shampoo.

Animal Type Insights

The companion animals segment dominated the market in 2024 due to the rise in pet ownership, public awareness, and demand for high-quality animal care. The segment includes pet animals such as dogs, cats, horses, rabbits, and other animals. As pet ownership and adoption rates increase globally, people are more willing to make more significant financial and time commitments to the well-being of their cherished pets. In 2024, pet ownership in the U.S. has reached notable levels, with approximately 66% of households, or about 86.9 million homes, owning at least one pet. The pet population continues to grow, with the dog population peaking at 89.7 million.

The livestock animals segment is expected to witness a lucrative CAGR during the forecast period. The cost of animal healthcare is increasing, especially in industrialized economies, due to the greater adoption of farm animals, which promotes market growth. The National Agricultural Statistics Service reported in July 2024 that the total amount spent on American farms in 2023 was USD 481.9 billion, up from USD 481.9 billion in 2022. The livestock animals segment is further subdivided into cattle and others. The market for veterinary dermatology drugs is anticipated to be driven by the incidence of parasitic infections in livestock animals and the rising demand for animal protein.

Route of Administration Insights

The topical segment dominated the market in 2024 and is expected to witness a lucrative CAGR during the forecast period. Topical drugs allow direct application to the affected area, ensuring the medication is delivered precisely where needed. This targeted approach reduces the risk of systemic side effects with oral medications. When medications are applied topically, they are absorbed locally through the skin. This limited absorption into the bloodstream helps minimize the risk of systemic toxicity and interactions with other medications the animal may be taking.

Moreover, many animals may resist taking oral medications, making it challenging to ensure they receive the full course of treatment. Topical drugs can be easier to apply, leading to better compliance and treatment success. Also, topical medications can often relieve localized skin problems quicker than systemic medications that take time to circulate throughout the body.

Distribution Channel Insights

The hospital pharmacies segment dominated the market with a revenue share of 62.36% in 2024 because more pet owners are taking their animals to hospitals for treatment. Additionally, their desire to spend money on their pets and the rise in skin disorders in these animals are boosting the market growth. Patient footfall in veterinary hospitals is rising significantly as most medication brands require obligatory veterinary monitoring before use.

The e-commerce segment is expected to witness a lucrative CAGR during the forecast period. Pet owners' quick transition to online shopping and the existence of major shops like Amazon, Walmart, Chewy.com, and PetCo are the primary factors contributing to the market growth for veterinary dermatology Products. These online merchants make it simple to choose and buy products with a quicker delivery method, which is fueling market growth. Moreover, online stores are accessible 24 hours a day, seven days a week, allowing customers to shop at their convenience, regardless of time zones or business hours.

Regional Insights

North America veterinary dermatology drugs market dominated and accounted for 38.29% in 2024. This can be attributed to the presence of key companies, high expenditure on pets, pet humanization, and rising awareness about animal disease. For instance, key market players, such as Zoetis; Merck & Co., Inc.; and Elanco Animal Health, are headquartered in the U.S. and are undertaking various strategic initiatives to increase their market share. Additionally, regulatory agencies, such as the FDA, continue to approve new treatments, allowing for more options for veterinarians and pet owners. Strategic partnerships between veterinary drug manufacturers and multinational companies are accelerating the development and distribution of dermatology products. For instance, in June 2023, Zoetis received FDA approval for Apoquel Chewable (oclacitinib chewable tablet), a new formulation for managing pruritus and atopic dermatitis in dogs 12 months and older. The chewable tablet offers comparable efficacy to the original Apoquel tablet and enhances medication compliance, making it easier for pet owners to administer. This product is expected to improve outcomes for dogs suffering from allergic skin conditions, with over 13 million dogs having been treated with Apoquel in the U.S. over the past decade.

U.S. Veterinary Dermatology Drugs Market Trends

The U.S. veterinary dermatology drug industry’s growth is driven by the increasing prevalence of skin disorders in pets, such as allergies, infections, and inflammatory conditions. As pet ownership rises and demand for advanced treatment options grows, the market is evolving with new and more effective therapies. Furthermore, expanding local players to provide adequate veterinary dermatology treatments in the U.S. supports regional market growth. For instance, in November 2023, Animal Dermatology Group (ADG) expanded its presence in Northern California and the Pacific Northwest by acquiring Animal Dermatology & Allergy in Rocklin, CA, and SkinVet Clinic in Lake Oswego, OR. These acquisitions enhance ADG's commitment to providing top-tier veterinary dermatology care across the U.S., with a network of nearly 70 doctors in 14 states.

Europe Veterinary Dermatology Drugs Market Trends

The Europe veterinary dermatology drugs industry is experiencing significant growth, driven by the rising prevalence of skin disorders in pets, particularly dogs. Canine skin diseases are an essential concern, with allergic skin disorders affecting around 25.47% of dogs in regions like the UK. Skin disorders account for approximately 12.58% of all canine health issues diagnosed in primary veterinary care, highlighting their prevalence. Factors such as breed, age, and environmental influences, like exposure to allergens and pollutants, contribute to the frequency of these conditions. There is a growing emphasis on preventive care, including regular vet check-ups and proper grooming, to manage and reduce the incidence of skin diseases in dogs.

Germany veterinary dermatology drugs market growth is driven by several key factors, including the rising prevalence of skin disorders in pets, particularly dogs, and the growing awareness among pet owners about the importance of skin health. The increasing demand for innovative treatments, such as biologics and targeted therapies for conditions like atopic dermatitis and pruritus, also contributes to market growth. Additionally, advancements in diagnostic techniques and a rising focus on preventive care encourage early detection and treatment of skin conditions. Moreover, the strong veterinary healthcare infrastructure and increasing pet ownership further support the market expansion in Germany.

Asia Pacific Veterinary Dermatology Drugs Market Trends

Asia Pacific is expected to witness the fastest CAGR over the forecast period. As economies in the Asia Pacific region continue to grow, there is a noticeable increase in the size of the middle-class population, higher disposable incomes, and growing urbanization. Market players have begun to capture opportunities in these emerging markets. China, in particular, shows strong momentum due to advancements in veterinary pharmaceuticals and government support for pet healthcare. For instance, in October 2024, FelicaMed Biotechnology was approved by China's Ministry of Agriculture and Rural Affairs for Lirucitinib, a Class I veterinary drug to treat canine pruritus. Licensed to Elanco's Chinese subsidiary, Lirucitinib is a JAK inhibitor that disrupts the itch-scratch-inflammation cycle, offering rapid relief. This collaboration marks a milestone in China's veterinary innovation and strengthens FelicaMed's commitment to advancing pet health solutions. Additionally, Partnerships between local companies and global leaders (e.g., FelicaMed and Elanco in China) are driving the introduction of innovative drugs designed for regional market needs.

The veterinary dermatology drugs industry in India is witnessing steady growth due to increasing pet ownership, rising awareness, and an increasing range of effective treatments designed to manage animal skin conditions. Canine and feline skin disorders, such as allergies, infections, and parasitic infestations, are common in India, with studies reporting a 12-27% prevalence in dogs. This contributes to a growing need for dermatology-specific treatments. Furthermore, Indian companies, along with multinational players like Elanco and Zoetis, are expanding their portfolios of veterinary dermatology drugs. For example, Lirucitinib, a JAK inhibitor for canine pruritus, has been licensed in India by Elanco. Other products, including anti-fungal and anti-bacterial agents, are marketed for treating skin infections.

Latin America Veterinary Dermatology Drugs Market Trends

The Latin America veterinary dermatology drugs industry is expanding due to increasing awareness of pet healthcare and rising skin conditions in animals. Key drivers include the growing pet population, increased adoption of veterinary dermatology treatments, and advances in drug formulations. The demand for effective treatments for conditions like atopic dermatitis, allergies, and parasitic infections particularly influences the market. Brazil, Mexico, and Argentina are significant contributors to the market's growth, focusing on innovative therapies and affordable solutions for pet owners.

The veterinary dermatology drugs market in Brazil is experiencing steady growth, driven by increasing awareness of animal health, expanding pet ownership, and a rise in skin-related issues among companion animals. Skin conditions such as allergies, infections, and parasitic diseases are common, leading to a higher demand for effective dermatological treatments. A study in Ilhéus, Bahia, found that 62.3% of dogs were infested with Tunga penetrans, a parasitic skin disease. Significant risk factors included semi-restricted living conditions and the presence of sand, with common clinical signs being edema and hyperkeratosis. The study highlights the high prevalence of tungiasis in the canine population and emphasizes the need for targeted interventions in areas with poor living conditions.

Middle East & Africa Veterinary Dermatology Drugs Market Trends

In the Middle East and Africa (MEA), veterinary dermatology therapies are seeing gradual growth driven by increased awareness of pet health and rising pet ownership in urban areas. Common treatments focus on conditions such as allergic dermatitis, parasitic infections, and fungal diseases. Antihistamines, corticosteroids, immunosuppressive drugs, and newer biologics like monoclonal antibodies are gaining popularity. Additionally, the market is evolving with a rise in specialized veterinary dermatology clinics, particularly in countries like the UAE, South Africa, and Saudi Arabia. However, challenges like limited access to advanced therapies in rural areas and economic constraints persist.

The South Africa veterinary dermatology drugs market is expected to grow during the forecast period. In South Africa, veterinary dermatology therapies are gaining traction due to rising awareness of pet health and an increasing number of animals suffering from skin disorders. The need for treatments for common conditions such as atopic dermatitis, allergic reactions, and parasitic infestations like ticks and fleas primarily drives the market growth. Popular therapies include corticosteroids, cyclosporine (e.g., Atopica), and newer treatments like Apoquel (oclacitinib) for pruritus control in allergic dermatitis. Additionally, South African veterinarians increasingly use immunotherapy and topical treatments like shampoos and sprays to manage skin conditions. A growing market for biologic therapies, such as monoclonal antibodies, offers long-term management options for chronic conditions.

Key Veterinary Dermatology Drugs Company Insights

The market is fragmented owing to numerous companies offering veterinary dermatology drugs. These organizations carry out a number of strategies to increase their market presence and share. These initiatives include mergers and acquisitions, partnerships and collaborations, product launches, R&D, regional expansion, and more.

Recent Developments

• In September 2024, Elanco launched Zenrelia (ilunocitinib tablets), a once-daily oral JAK inhibitor for managing allergic and atopic dermatitis in dogs aged 12 months and older. Zenrelia offers significant itch relief and affordability, making it a safer, more effective alternative to competitors.

• In August 2024, Boehringer Ingelheim India formed a strategic distribution partnership with Vvaan Lifesciences Pvt Ltd to enhance its pet parasiticide portfolio and expand its reach in India's pet health market, valued at around USD 124.51 million. This collaboration aims to improve access to quality pet healthcare in Tier 2 and underserved cities, leveraging Vvaan's expertise to better serve these regions and elevate veterinary care standards across the country.

Veterinary Dermatology Drugs Market Report Scope

Global Veterinary Dermatology Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global veterinary dermatology drugs market report on the basis of indication, type, animal type, route of administration, distribution channel, and region:

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Parasitic Infections

  • Allergic Infections

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescription

  • OTC

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Companion Animals

    • Dogs

    • Cats

    • Horses

    • Others

  • Livestock Animals

    • Cattle

    • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Topical

  • Oral

  • Injectable

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail

  • E-commerce

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Rest of Europe

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

    • Rest of Asia Pacific

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA